We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Automated Chemiluminescent Assays Evaluated for Heparin-Induced Antibodies

By LabMedica International staff writers
Posted on 30 Aug 2012
Two recently introduced automated chemiluminescent assays for the detection of antibodies have been evaluated in the diagnosis of heparin-induced thrombocytopenia.

The performance of the two assays was compared with enzyme linked immunosorbent assays (ELISA) heparin-induced antibodies (HIA) tests for immunoglobulins IgG and IgAM. More...


Scientists at Ghent University Hospital (Belgium) collected citrated plasmas from 87 patients with clinical suspicion of heparin-induced thrombocytopenia (HIT) were analyzed with all four assays and with a functional confirmation assay. The Zymutest HIA IgG and HIA IgGAM assays (Aniara; West Chester, OH, USA) are micro-ELISAs, that take over two hours to perform, were used as the standard reference.

The fully automated quantitative chemiluminescent immunoassays, the HemosIL AcuStar HIT-IgG (Platelet Factor 4-Heparin, PF4-H), specific for IgG anti-PF4/H antibodies, and the HemosIL AcuStar HIT-Ab (PF4-H), detecting IgG, IgM and IgA anti-PF4/H antibodies are products of Instrumentation Laboratory (Bedford, MA, USA). They provide enhanced detection of HIT antibodies in specialty and hospital hemostasis laboratories. Unlike existing manual processes, the ready-to-use, cartridge-based assays offer results in approximately 30 minutes.

The sensitivities of all assays were 100%. The Acustar HIT-IgG assay showed 85% specificity compared to the 73% for the HIT-Ab assay using the manufacturer’s cutoffs. Specificities of all assays, except for the AcuStar HIT-IgG, could be significantly improved when altering the cutoff. Titers were significantly higher for the HIT-Ab assay compared with the HIT-IgG assay. This was also the case for the patients with confirmed HIT indicating that the cutoff of 1.0 Optical Density (OD) for both AcuStar assays, as proposed by the manufacturer, can be adapted for the AcuStar Hit-Ab assay resulting in an increased specificity.

Chemiluminescent technology provides analytical excellence through an expansive working range for high sensitivity and precision allowing clinicians to make timely, well-informed therapeutic decisions. In addition, the Acustar HIT precalibrated reagent cartridges offer significant time- and cost- efficiencies. The study was published in the August 2012 edition of the International Journal of Laboratory Hematology.

Related Links:

Ghent University Hospital
Aniara
Instrumentation Laboratory



Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.